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HepatocarcinogenesisThe nonsense mutations of the hepatitis B virus (HBV) surface (S) gene have been reported to have oncogenic
potential. We have previously identiﬁed several transforming nonsense mutations of the HBV S gene from
hepatocarcinoma (HCC) patients. Among them, the sW182*mutant (the stop codon for tryptophan 182) showed
the most potent oncogenicity in a mouse xenograft model using stably transfected mouse ﬁbroblast cells. This
study is aimed at understanding the molecular mechanisms leading to the oncogenic activity of the sW182*
mutant.
A gene expression microarray in combination with gene set enrichment analysis (GSEA) revealed differentially
expressed gene sets in the sW182* cells, including those related to cell-cycle regulation, deoxyribonucleic acid
repair, and genome instability. Of the differentially expressed genes, the transforming growth factor-β-induced
(TGFBI) gene was further validated to be dysregulated in the sW182* cells. This dysregulation was accompanied
by hypermethylation of the TGFBI promoter.
The level of cyclin D1, a negatively regulated TGFBI target, was highly elevated in the sW182*mutant cells, which
is consistent with the potent oncogenicity. Furthermore, frequent abnormal mitosis and multinucleation were
observed in the mutant cells. Exogenous expression of TGFBI alleviated the oncogenic activity of the sW182*
cells. In human HBV-related HCC cancerous tissue, expression of TGFBI was downregulated in 25 of the 55
(45%) patients examined, suggesting that TGFBI dysregulation could occur in HBV-related HCC development in
some cases.
These results suggest that dysregulation of TGFBI is involved in the oncogenic activity of the sW182* mutant of
the hepatitis B virus S gene.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the major cancers in the
world and among the leading causes of cancer death [1]. Although theing growth factor-β-induced;
ntigen; GSEA, gene set enrich-
reaction; CREB, cyclic AMP-
isulﬁte restriction analysis; 5-
, DNA methyltransferase
d Genomic Medicine, National
oli 350, Taiwan. Tel.: +886 37association between chronic hepatitis B virus (HBV) infection and HCC
has been well established [2–4], whether HBV plays a direct role in
hepatocarcinogenesis remains uncertain. In most HBV-related HCC pa-
tients, the development of liver cancer is a long-term process, with
liver cirrhosis preceding the cancer. In some patients, however, HCC de-
velopment without cirrhosis has been reported, suggesting that viral
factor(s) alone could also play a direct role in hepatocarcinogenesis
without invoking chronic liver inﬂammation.
Nonsense mutations of HBV PreS/S gene have been reported to
induce transcriptional transactivation activity, suggesting that these
mutations may contribute to HBV-associated oncogenesis [5,6]. The
PreS/S gene has one long open reading frame with three in-frame
“start” (ATG) codons. Accordingly, the gene is divided into three sec-
tions (pre-S1, pre-S2, and S), and three proteins with different sizes
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pre-S1 + pre-S2 + S, pre-S2 + S, and S, respectively. Previously, we
identiﬁed multiple nonsense mutations of the HBV S gene in HBV-
related HCC patients who had developed HCC after lamivudine treat-
ment [7,8]. Our studies demonstrated that such nonsense S mutants
could transactivate oncogene promoters and increase tumorigenicity
in a xenograft model using the construct of the whole PreS/S gene
with the nonsense mutations.
Furthermore, we identiﬁed by immunohistochemical staining 25
HBV-relatedHCCpatientswhowere positive for hepatitis B core antigen
(HBcAg) in their HCC tissue, suggesting the presence of replicative HBV
in the cancerous part. We performed whole HBV genome mutation
analyses in these 25 paired HCC tissue samples and identiﬁed a recur-
rent nonsense mutation at the codon for tryptophane 182 (sW182*)
in the cancerous part of the HCC tissues [9]. Mouse xenograft and
in vitromigration assays revealed that thismutant has potent oncogenic
activity [9]. Recently, Lee et al., in their independent study, found the
sW182* mutation in HBV patients in Korea. They also demonstrated
the oncogenic potential of the sW182* mutant using NIH3T3 cell line
[10].
We have also generated NIH3T3 cell lines stably transfected with
wild-type PreS/S gene or PreS/S gene with the sW182* mutation, and
performed gene expression microarray analysis to search for candidate
genes thatmay be involved in themutant-induced hepatocarcinogenesis.
Marked downregulation of the transforming growth factor-β-induced
(TGFBI) gene in the sW182* mutant clones was identiﬁed. Thus, we
have performed a series of functional analyses to clarify the signiﬁcance
of TGFBI downregulation in the oncogenic activity of the sW182*mutant.
TGFBI, also known as βig-H3, was originally discovered as a TGF-β-
inducible gene in a human adenocarcinoma cell line [11]. Its association
with corneal dystrophy has been widely accepted [12]. TGFBI has also
been reported to play a role in a wide variety of pathological conditions
including tumorigenesis. Loss or reduced expression of TGFBI has been
associated with lung, breast, and ovarian cancers [13–15]. Moreover,
TGFBI-deﬁcientmice develop various kinds of tumors, including liver tu-
mors, accompanied by upregulation of cyclin D1 and increased chromo-
somal aberration [16]. On the other hand, a signiﬁcant number of
reports have stated that TGFBI may also function as a tumor promoter
[15,17–19]. It has been suggested that this functional difference of
TGFBI may depend on the tumor microenvironment [15]. High expres-
sion of TGFBI seems to be related to more metastatic tumors [18,19],
whereas a low level of TGFBI appears to promote tumor initiation and
development [16].
This studyprovides for theﬁrst time a link between the nonsensemu-
tation of the HBV S gene and the TGFBI pathway in hepatocarcinogenesis.2. Materials and methods
2.1. Cell culture and constructs
NIH3T3 cells were maintained in Dulbecco's Modiﬁed Eagle's Medi-
um (DMEM) supplemented with 10% calf serum, 2 mM glutamine,
100 unit/ml penicillin, and 100 μg/ml streptomycin. The vector
pIRESbleo (Addgene, Cambridge, MA, USA) was used for the construct.
Transfections with plasmids containing the wild-type of the whole
PreS/S gene and the PreS/S genewith the sW182*mutation, respective-
ly, were performed using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's instructions. After
Zeocin (Invitrogen, Carlsbad, CA, USA) selection, several stable cell
clones were isolated for “vector”, “wild-type” and “mutant”. These
cells were maintained with occasional treatments with 0.1 mg/ml
Zeocin.
Human TGFBI cDNA was cloned in pBABEpuro vector (Addgene,
Cambridge, MA, USA) by reverse transcriptase polymerase chain reac-
tion (RT-PCR) from HaCaT human keratinocytes. The sW182* mutantcell lines (clone 6) were retrovirally transduced with this construct or
pBABE-GFP (control) as described previously [20].
The reporter plasmid for the TGFBI promoter was constructed as fol-
lows. Fragments containing 1000 bp upstream of the TGFBI transcrip-
tion initiation site were generated by PCR from genomic DNA from
HaCaT cells. The primer sequences are as follows: 5′-GAA TGG TAC
CCT TCA TGG AAC ATC ATT GGC TTG GG-3′ (forward) and 5′-GTT TAA
GCT TGG AGC GGG ACG ACG CGC ACC-3′ (reverse). KpnI (forward)
and HindIII (reverse) sites (underlined)were introduced in the primers
for cloning into pGL3-Basic vector (Promega, Madison, WI).
2.2. Gene expression microarray proﬁling and pathway/gene set analysis
Gene expression microarray proﬁling experiments were previously
described [21]. The microarray data has been deposited in the GEO da-
tabase under accession number GSE50180.
Gene set enrichment analysis (GSEA) [22]was used to obtainmolec-
ular pathways or annotated gene sets enriched in the sW182* mutant
clones compared to wild-type clones. The data were derived from an
average of two independent clones. “Difference of classes”with 100per-
mutations was used for the analysis.
2.3. Quantitative polymerase chain reaction (qPCR) for TGFBI
Cells were serum-starved (0.2% fatal bovine serum (FBS)) for 16 h
before treatment with (or without) 0.5 nM TGF-β (PeproTech Asia,
Rehovot, Israel) for 7 h. Total RNA was prepared by using TRIzol
(Invitrogen, Carlsbad, CA, USA). The ﬁrst strand of cDNA was synthe-
sized from 1 μg total RNA using a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA, USA). Q-PCR was
run on a CFX96 Real-Time System (Bio-Rad, Berkeley, CA, USA) with a
KAPA SYBR FAST qPCR kit (KAPA Biosystems, Cape Town, South
Africa). The GAPDH gene was used as an internal standard for
normalization.
2.4. Reporter assay
Control, wild-type, and mutant cells were transfected with the re-
porter construct, along with a pRL-TK Renilla reporter. Cells were treat-
ed with 0.5 nM TGF-β for 24 h in low-serum medium (0.2% FBS).
Luciferase activity was measured using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI).
2.5. Antibodies, Western blot, and immunoﬂuorescence microscopy
Antibodies used in the studywere purchased from the following sup-
pliers: cyclin D1 [EPR2241], CREB [E306], phospho-CREB (pSer133)
[E113], and phospho-Smad3 (pSer423/425) [EP8235] from GeneTex
(San Antonio, TX, USA); actin from Santa Cruz (Dallas, TX, USA); TGFBI
(k1H12) and Smad3 [MO5] from Abnova (Walnut, CA, USA); and α-
tubulin from Epitomics (Burlingame, CA, USA). Horseradish peroxidase-
conjugated secondary antibodies were from Pierce (Rockford, IL, USA).
For the protein lysate preparation, cells were cultured in a low-serum
medium for 24 h before they were lysed. When treated with TGF-β,
cells were further incubated with 0.5 nM of the cytokine for various
time periods before being lysed. TheWestern blot procedure was as pre-
viously described [20]. The levels of cyclin D1 and pCREBwere quantitat-
ed by using Adobe Photoshop CS5 (Adobe Systems, San Jose, CA, USA).
Actin and CREB protein, respectively, were used as controls for
normalization.
For immunoﬂuorescence microscopy, cells with 50–60% conﬂuence
were ﬁxed and incubated with an α-tubulin antibody (1:100). α-
Tubulin was visualized by Alexa Flour 594 goat anti-rabbit IgG (Life
Technologies, Carlsbad, CA, USA). Nuclei were stained with 4′,6-
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO, USA).
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Cells were treated (or untreated) with TGF-β for 7 h in a low serum
medium. After treatment, genomic DNA was prepared using the
QIAampmini kit (QIAGEN, Germantown,MD, USA). Bisulﬁte conversion
of the genomic DNA (500 pM) was performed using the EZ DNA
Methylation-Gold Kit (Zymo Research, Irvine, CA, USA). Combined bi-
sulﬁte restriction analysis (COBRA) primer-ampliﬁed PCR products
were puriﬁed using the DNA Clean & Concentrator-5 (Zymo Research,
Irvine, CA, USA), digested by BstUI (New England BioLabs, Ipswich,
MA, USA), and separated on a 3% agarose gel.
The primers used for COBRA were designed based on the Li Lab pro-
gram (http://www.urogene.org/methprimer/). The primers used were
as follows:
5′-TGAATATTTTAAGAAATTGAAATTTGAG-3′,
5′-AAACCCACAAACAATACCAAAAC-3′.
A 320 bp PCR product ampliﬁed from the unmethylated template
that was resistant to the restriction enzyme (BstUI) was indicated as
“unmethylated” (Fig. 3). For DNA demethylation, cells were treated
with 10 μM 5-azacytidine (5-Aza) (Sigma-Aldrich, St. Louis, MO, USA)
for 4 days before being subjected to qPCR analysis. 5-Aza was present
throughout the experiment.
2.7. Mouse xenograft assay
Nudemicewere obtained from theNational Laboratory Animal Cen-
ter, Taiwan. Cells were grown to ~60% conﬂuence before being harvest-
ed and thenmixedwithmatrigel (BD Biosciences, San Jose, CA, USA) for
injections. Groups of four or ﬁvemicewere injectedwith the cell lines of
vector, wild-type, and themutant, respectively (1 × 106 cells/injection).
At the end of the experiment, the tumors were extracted and weighed.
The p-value was obtained from Student's t-test. All animals in this ex-
periment received human care. The study protocol complied with our
institution's guideline and was approved by the Animal Research Ethics
Committee at the National Health Research Institutes, Taiwan (IACUC
Approval No. 100077).
2.8. Analysis of TGFBI expression in human HCC tissue by qPCR
Fresh frozen tumor tissues and paired benign liver tissue of 55 HBV-
related HCC patients who received surgical operation in Chang-Gung
Memorial Hospital during the years 2000–2002, were obtained with
signed informed consent from the tumor bank of CGMH for the HBV-
related carcinogenesis studies. The patients' clinical data were obtained
from medical records. This protocol was approved by the Institutional
Review Board of Chang-Gung Memorial Hospital. RNA was extracted
from the fresh frozen tissues by Trizol and subjected to qPCR for TGFBI
expression.
2.9. Nucleotide sequence of HBV PreS/S gene
For sequencing analysis, we used 3 pairs of primers to cover the
preS/S gene of HBV. For ampliﬁcation, we used the following 3 pairs of
primers:
• preSF 5′-GAGAGTCCACACGTAGCG-3′,
• preSR 5′-GACTCTGTGGTATTGTGAGG-3′,
• SF 5′-GGACCCTGTACCGAACATG-3′,
• SR 5′-GTTCCTGTGGCAATGTGCC-3′,
• preSF2 5′-CTCACAACTGTGCCAGCAGC-3′,
• SR2 5′-CCTTGATAGTCCAGAAGAACC-3′.
The PCR amplicons were subjected to direct sequencing on an
ABI3730 genetic analyzer (Applied Biosystems, Foster City, CA). Se-
quence variations were determined using Seqscape software (AppliedBiosystems, Foster City, CA, USA). The HBV reference sequences were
AY167089 for genotype B and AY167095 for genotype C (National Cen-
ter for Biotechnology Information).
3. Results
3.1. Gene expression microarray proﬁling
Lee et al. recently used transfected NIH3T3 cell lines to demonstrate
an increased transformation ability of the sW182*mutant [10].We thus
employed the same system to investigate the molecular basis of how
the nonsensemutation potentiates the oncogenicity. To obtain informa-
tion on the differentially expressed genes in the mutant cells, we ﬁrst
performed gene microarray analysis of NIH3T3 cell clones stably
transfected with wild-type PreS/S and the sW182* mutant. A total of
349 gene probes were found to have at least 2-fold (average) differen-
tial expression between the mutant and wild-type cell groups. In
order to know what biological pathways or curated gene sets could be
involved in the phenotypic differences between wild-type and mutant
clones, we performed gene set enrichment analysis (GSEA). From the
GSEA, the differentially expressed genes between two groups were
found to be signiﬁcantly enriched by gene sets associated with a wide
variety of cancer-related pathways. For examples, many genes involved
in regulation of mitotic cell cycle or mismatch repair were signiﬁcantly
enriched in the sW182* mutant group (Fig. 1A–B). Likewise, the gene
set “Boyault Liver Cancer Subclass G123 UP”, which is the common
gene expression signature of several sub-groups of HCC patients having
the phenotype of chromosomal instability [23], was also signiﬁcantly
enriched in the differential expression analysis (Fig. 1C).
Of note, the TGFBI gene was signiﬁcantly downregulated in the cells
bearing the sW182*mutant (Fig. 1D). Since TGFBI is considered a tumor
suppressor, we focus on this factor in relation to the HBV PreS/S sW182*
mutation.
3.2. Dysregulation of TGFBI in the sW182* mutant cells
To validate the result above, levels of the TGFBI gene as well as pro-
tein were examined in detail by means of qPCR, reporter assay, and
Western blot. Fig. 2A shows that the level of Smad5, which can serve
as a control, was comparable among the three cell lines. Strikingly, the
TGFBI gene was very low in the mutant cells. Furthermore, whereas
the gene responded to TGF-β in vector-control and wild-type cells, the
responsewas not seen in themutant cells. All independent clones tested
showed similar results (Fig. 2B), indicating that the observed TGFBI dys-
regulation in the sW182* mutant cells was not due to clonal variation.
Vector clone 4, wild-type clone 3, and mutant clone 6 (Fig. 2B) were
used as representative clones in this study unless otherwise indicated.
In a reporter assaywith a TGFBI promoter construct, luciferase activ-
ity was induced by TGF-β in vector-control and wild-type cells, but not
in themutant cells (Fig. 2C). This resultwas consistentwith that of qPCR
(Fig. 2B). The TGFBI protein levels in vector andwild-type cells were in-
creased in response to TGF-β treatment, but remained low in the mu-
tant cells (Fig. 2D). Smad3 was equally phosphorylated in each cell
line in response to TGF-β, indicating that TGF-β signaling per se was
not affected bywild-type PreS/S or by themutant (Fig. 2E). These results
together implied that the TGFBI gene and protein were speciﬁcally dys-
regulated in the sW182* mutant cells.
3.3. Hypermethylation of the TGFBI promoter in the sW182* mutant cells
Promoter hypermethylation is one of the important mechanisms for
the TGFBI gene silencing in cancer cells [15,24]. To test this possibility
with our system, methylation status of the TGFBI promoter region was
analyzed by COBRA (Fig. 3A). In the putative CpG island region of the
promoter, methylation was detected in each cell line. A signiﬁcant
amount of the unmethylated form also existed in the vector-control
Fig. 1. Enrichment of gene sets/pathways and downregulation of TGFBI in the sW182*mutant cells. Three pathways/gene sets associatedwith (A) cell cycle regulation, (B) DNA repair, and
(C) genome instability were signiﬁcantly enriched in the differential gene expression proﬁle between groups of wild-type cells and the mutant cells, as analyzed by GSEA. ES, enrichment
score. A negative value of ESmeans that the gene set/pathway is negatively correlatedwith the referred group of cells. (D) TGFBI levelmeasured by Illumina Beadchipsmicroarray analysis.
Vector, vector clone; WT, wild-type clones; MT, sW182* mutant clones.
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sW182* mutant cells, indicating hypermethylation of the promoter in
themutant cells. Treatment with a demethylation agent (5-Aza) result-
ed in a 5-fold increase of the TGFBI transcription level in the mutant,
whereas the drug had no effect on vector-control or wild-type cells
(Fig. 3B).
3.4. Tumorigenic activity of the sW182* cells associated with elevated
expression of cyclin D1 and abnormal mitosis
The level of cyclin D1, a protein that can be negatively regulated by
TGFBI, was found to be highly elevated in the sW182* mutant cells
(Fig. 4A), in which the TGFBI level was dysregulated (Fig. 2). Cyclin D1
can be regulated through various signals and transcription factors. In
TGFBI deﬁcient mice, the high cyclin D1 level is accompanied by aber-
rant activation of cyclic AMP-responsive element binding protein
(CREB), one of the transcription factors regulating cyclin D1 [16]. Con-
sistent with this observation, elevated CREB activation, judged by its
phosphorylation level, was also observed in the sW182* mutant cells(Fig. 4A). These effects by the mutant were also observed in the TGF-
β-treated cells (Supplementary Fig. 1).
TGFBI has been implicated in microtubule stabilization, and loss
of TGFBI can induce mitotic abnormalities [25]. Immunoﬂuorescence
staining with α-tubulin was performed to reveal microtubule struc-
tures and nuclear morphology. A signiﬁcantly higher proportion of
abnormal cells with multinuclei was observed in the mutant cells
compared to wild-type cells (mutant 11%, wild-type 0.8%, n = 500)
(Fig. 4B). In addition, abnormal mitotic ﬁgures with multipolar spin-
dle were frequently found in cells harboring the sW182* mutant
(16.7% of mitotic cells), but were rare in wild-type cells (b1%)
(Fig. 4B).
To test the tumorigenic activity, vector-control, wild-type, and the
mutant cells, respectively, were xenografted into mice. All 5 nude
mice subcutaneously injected with the sW182* cells had tumor forma-
tions 4 weeks after injection, whereas those with wild-type or vector-
control cells did not (Fig. 4C). These results suggested the increased cy-
clin D1 and abnormal mitosis account for the potent tumorigenic activ-
ity of the sW182* cells.
Fig. 2. The TGFBI gene and protein were dysregulated by the sW182*mutant. (A) Levels of Smad5 in vector-control, wild-type, and mutant cells, as measured by qPCR. Means± SD from
triplicated experiments are shown. (B) TGFBI level measured by qPCR inmultiple clones and their response to TGF-β. The level in the vector clone 3was used for normalization. Cells were
treated with TGF-β for 7 h. (C) TGFBI reporter assay. Cells were treated with TGF-β for 24 h before the luciferase activity wasmeasured. (D) TGFBI protein level analyzed byWestern blot
after TGF-β treatment for indicated time periods. (E) Smad3 phosphorylation level analyzed by phospho-Smad3 Western blot after TGF-β treatment for 45 min.
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cells
To show that these effects by the sW182*mutant were attributed to
dysregulated TGFBI, the protein was exogenously expressed by retrovi-
ral transduction. Green ﬂuorescent protein (GFP) was also transduced
as a control. The exogenous TGFBI signiﬁcantly reduced cyclin D1 and
pCREB, as demonstrated by Western blot (Fig. 5A). Four nude mice in
a group were subcutaneously injected with the sW182* cells with GFP
(control) or TGFBI, respectively, and the resulting tumors wereFig. 3.Hypermethylation of the TGFBI promoter in the sW182*mutant cells. (A) Theputative Cp
cells was analyzed by COBRA formethylation status. The unmethylated form (unmethylated) w
PCR products from themethylated template are indicated (methylated). The difference in them
levels ofmethylation in the region. (B) Effect of aDNAmethyl transferase inhibitor (5-Aza) on th
cells (DMSO). Relative value to control (=1) is shown.compared. Both GFP- and TGFBI-transducedmutant cells had tumor for-
mation with 100% incidence; but the tumor size was signiﬁcantly re-
duced with TGFBI-transduced cells (Fig. 5B). These results suggested
that the dysregulated TGFBI in sW182* cells is involved in the tumori-
genic activity.
3.6. TGFBI expression in human HCC tissue
Among the 55 HBV-related paired HCC and non-tumor liver tissue
samples, 25 tumors (25/55, 45.45%) displayed downregulated TGFBI inG island region of the TGFBI promoter in the vector-control,wild-type, and sW182*mutant
as absent in themutant cells, indicating hypermethylation of the promoter inmutant cells.
ethylation patterns betweenwild-type and themutant indicates the alteration of sites and
e TGFBI transcription. In eachpanel, TGFBI expressionwas comparedwith that in untreated
Fig. 4. TGFBI is involved in the oncogenic activity of the sW182*mutant. (A) Increased expression of cyclin D1 in the sW182* cells, comparedwith that in the vector-control andwild-type
cells. Cell lysatewas analyzed byWestern blot using indicated antibodies. Actin, pCREB, and CREB are also shown (upper panel). Lower panels show the levels of cyclin D1 and pCREB from
two independent preparations (means± SD). Values are expressed relative to vector control (=1). (B) Frequent abnormal mitosis in sW182* cells compared with wild-type. Cells were
stained byα-tubulin antibody and DAPI. Left panel, interphase cells. Arrowheads indicate cells with multiple nuclei. Right panel, cells inmetaphase. (C) Nudemice xenograft tumorigenic
assay.Micewere subcutaneously injectedwith the cells (vector, wild-type (WT) ormutant (MT)). Fourweeks post-injection, a tumorwas observed only in themice that had received the
sW182* mutant cells. The mice are shown in the upper panel. Tumor weight is quantitated in the lower panel.
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pathological characteristics of the 55 patients are shown in Table 1.
Downregulation of TGFBI was associated with higher tumor stage (p
= 0.0323). Sequencing of HBV PreS/S gene revealed 6 patients with
the sW182* mutation in the cancerous part of the liver tissue. Among
these 6 patients, the level of TGFBI expression was downregulated in 3
(3/6, 50%).
4. Discussion
We previously identiﬁed 4 different nonsense mutations of HBV S
gene with transformation activity — sL21*, sW156*, and sW172* [7,8],
and sW182* [9] in HBV-related HCCs— suggesting that these nonsense
mutations may play an important role in hepatocarcinogenesis. But the
underlying mechanism remained uncertain. In the current study, we
performed gene expression microarray combined with GSEA to obtain
differential gene expression proﬁles of the sW182* cells comparedFig. 5. Exogenous TGFBI inhibits tumorigenic ability of the sW182* cells. (A) Exogenous TGFBI r
Cell lysatewas analyzed as in Fig. 4A (upper panel). Exogenous TGFBI expressionwas also exami
in the lower panel as in Fig. 4A. (B) Tumor sizewas signiﬁcantly reducedwith TGFBI-transduced
quantitation (n = 4) (right panel) are shown. The p-value was obtained by Student's t-test.with wild-type cells. Consistent with the oncogenic activity, gene sets
related to regulation of cell cycle, DNAmismatch repair, and genome in-
stability were altered in the sW182* cells (Fig. 1A–C). TGFBIwas among
the genes differentially expressed in the mutant cells (Fig. 1D). TGFBI
was validated to be indeed dysregulated in the cells containing the
sW182* mutant, but not in those with the wild-type PreS/S gene
(Fig. 2). This study provides for the ﬁrst time a link between HBV
PreS/S gene and TGFBI pathway.
Silencing of tumor-suppressor genes is thought to be one of the
major causes of cancer. As a tumor suppressor, the TGFBI gene is often
silenced in many types of cancers, and hypermethylation is a major
mechanism for inactivation of the promoter [15,24,26,27]. Our results
clearly show that the sW182* mutant could induce hypermethylation
of the TGFBI promoter (Fig. 3). Certain factors have been reported to
bring DNA methyltransferases (DNMTs) to the promoter region of tar-
get genes [28,29]. It is possible that the sW182* mutant could gain an
ability similar to that of those factors, although products of the PreS/Seduces the cyclin D1 level. The sW182* cells were transduced with GFP (control) or TGFBI.
ned. The levels of cyclinD1 and pCREB from two independent preparations are quantitated
cells in the xenograft assay. Two representativemice, extracted tumors (left panel) and the
Fig. 6. TGFBI expression in 55 HBV-related HCC patients. qPCR analysis for TGFBIwas per-
formedwith tumor (T) and the adjacent normal tissue (N). For each case, Log10 of the T/N
ratio in TGFBI expression is shown. Asterisks indicate the patients in which the sW182*
mutation was detected.
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a DNA methyltransferase. The HBV X gene (HBx) has been shown to
promote hypermethylation of certain gene promoters, such as
p16INK4A [30,31]. In the case of the p16INK4A promoter hypermethyla-
tion, HBx transcriptionally upregulates DNMT1 through activation of
the cyclin D1–CDK4/6–pRb-E2F pathway [30]. In the sW182* cells, this
pathway may also be activated due to elevated cyclin D1 expression
(Fig. 4). If so, it is possible that, in the mutant cells, the TGFBI promoter
hypermethylation might be achieved by a mechanism similar to that
seen with HBx. Indeed, our microarray and qPCR data showed a much
higher expression of DNMT1 in the mutant cells (data not shown).
DNMT1 has been reported to be one of the epigenetic silencing effectors
and to play an important role in K-ras-mediated transformation of
NIH3T3 cells [32]. Further study is necessary for validation and a possi-
ble role of DNMT1 in sW182*-mediated oncogenic activity.
Zhang et al. reported that TGFBIdeﬁciency increased the incidence of
spontaneous tumor formation, including liver tumor, through upregula-
tion of cyclin D1 [16]. Their study implied that TGFBI deﬁciency per se
could induce tumors (37% incidence by 20 months) and that it alsoTable 1
Clinical characteristics of 55 HBV-related HCC patients with TGFBI data.
Variables TGFBI expression status
(T/N ratio)
p-Valuea
T b N T N N
Total number of patients 25 (45.45%) 30 (54.55%)
Gender 0.3406
Male 21 (50.00%) 21 (50.00%)
Female 4 (30.77%) 9 (69.23%)
Median age (range) 56 (18–72) 46 (26–74) 0.4984
≤65 years 19 (43.18%) 25 (56.82%)
N65 years 6 (54.55%) 5 (45.45%)
Tumor size (cm) 0.0509
≤2 2 (18.18%) 9 (81.82%)
N2 23 (52.27%) 21 (47.73%)
Cirrhosis 0.5391
Positive 17 (48.57%) 18 (51.43%)
Negative 8 (40.00%) 12 (60.00%)
Pathology stageb 0.0323
I 3 (20.00%) 12 (80.00%)
NIc 22 (55.00%) 18 (45.00%)
HCC, hepatocellular carcinoma; TGFBI, transforming growth factor-β-induced; T, tumor
tissue; N, paired benign liver tissue.
a Chi-square association test or Fisher's exact test (when there is cell frequency less
than 5).
b According to the sixth edition of Cancer Staining Manual by the American Joint Com-
mittee of Cancer [34].
c There were 24 stage II patients, 15 stage III patients, and 1 stage IV patient.increased sensitivity to carcinogens. This implication is reasonable, as
cyclin D1 is a well-known proto-oncogene [31,33]. Our observation is
reminiscent of their report (Fig. 4A and C). Difference of tumor inci-
dence between TGFBI-deﬁcient mice and our xenograft model is most
likely simply due to different systems used, but it may also be due to
the involvement of other oncogenic pathways in the sW182* mutant
cells (see below).
TGFBI could also induce microtubule stabilization, and loss of TGFBI
would result in mitotic spindle abnormalities [25]. This was exactly
what we found in the sW182* mutant cells (Fig. 4B). Taken together,
our results suggest that the sW182*mutant was sufﬁcient to inducemi-
totic abnormalities, which may be due to dysregulation of TGFBI.
Forced expression of TGFBI alleviated, but did not abolish, tumor for-
mation by the sW182* mutant (Fig. 5). This suggests that the oncogenic
activity of the mutant involves multiple mechanisms. Our microarray
data support this assumption (Fig. 1A–C). Three gene sets— comprising
cell cycle regulation, DNA repair, and genome instability—were all dif-
ferentially regulated in the sW182* mutant cells compared with wild-
type cells.
We also have examined TGFBI expression in HBV-related HCC tissue
by qPCR; nearly half of the tumors (25/55, 45.45%) showed downregu-
lation of TGFBI compared with paired benign liver tissue. The sW182*
mutation was identiﬁed in 6 HCCs; and half of those 6 tumors had
downregulated TGFBI. Since tumor incidence of TGFBI-deﬁcient mice is
not 100% [16], it is justiﬁable that low TGFBI does not necessarily corre-
late with HCC in the clinical samples. Rather, our data simply indicates
that TGFBI-low-type HCC cases indeed exist. It will be worth examining
the statuses of the TGFBI promotermethylation, cyclin D1 and pCREB in
sW182* mutant-positive as well as -negative samples. In addition, we
speculate that the patients with low TGFBImay be more vulnerable to
carcinogenic stimuli.
5. Conclusion
The present study provides evidence that the nonsense mutation
(sW182*) of the HBV S gene can directly induce tumor growth and
that dysregulation of TGFBI is involved in this oncogenic process. This
can provide new insights into the mechanism of HBV-related
hepatocarcinogenesis. Future studies using more physiological condi-
tions (use of hepatocytes and/or transgenic animals) will be needed to
further strengthen our observation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.03.007.
Conﬂict of interest
The authors declare no competing interests.
Acknowledgments
We thankDr. Shao-WinWang andMs. Chien-ChihHuang for techni-
cal support.
This work was supported by grants from the National Health
Research Institutes (NHRI-A1-MG-093-PP-04, NHRI-A1-MG-096-PP-
04, NHRI-A1-MG-98-PP-04, NHRI-A1-MG-100-PP-04, NHRI-A1-MG-
100-PP-09, NHRI-A1-MG-101-PP-09, and NHRI-A1-MG-102-PP-09),
DOH101-TD-C-111-004 and the National Science Council, Taiwan
(NSC92-2320-B-400-002, NSC97-2320-B-400-006-MY3, and NSC102-
2319-B-4-001).
References
[1] A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics,
CA Cancer J. Clin. 61 (2011) 69–90.
[2] R.P. Breasley, Hepatitis B virus: the major etiology of hepatocellular carcinoma,
Cancer 61 (1988) 1942–1956.
1087S.S. Jiang et al. / Biochimica et Biophysica Acta 1842 (2014) 1080–1087[3] M. Feitelson, Hepatitis B virus infection and primary hepatocellular carcinoma, Clin.
Microbiol. Rev. 5 (1992) 275–301.
[4] W.S. Robinson, Molecular events in the pathogenesis of hepadnavirus-associated
hepatocellular carcinoma, Annu. Rev. Med. 45 (1994) 297–323.
[5] A.S. Kekulé, U. Lauer, M. Meyer, W.H. Caselmann, P.H. Hofschneider, R. Koshy, The
pre-S2/S region of integrated hepatitis B virus encodes a transcriptional
transactivator, Nature 343 (1990) 457–461.
[6] U. Lauer, L. Weiss, P.H. Hofschneider, A.S. Kekulé, The hepatitis B virus pre-S/S(t)
transactivator is generated by 3′ truncations within a deﬁned region of the S gene,
J. Virol. 66 (1992) 5284–5289.
[7] M.W. Lai, S.F. Huang, C.W. Hsu, M.H. Chang, Y.F. Liaw, C.T. Yeh, Identiﬁcation of non-
sense mutations in hepatitis B virus S gene in patients with hepatocellular carcino-
ma developed after lamivudine therapy, Antivir. Ther. 14 (2009) 249–261.
[8] C.T. Yeh, T. Chen, C.W. Hsu, Y.C. Chen, M.W. Lai, K.H. Liang, T.C. Chen, Emergence of
the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients
with lamivudine-resistant chronic hepatitis B, BMC Cancer 11 (2011) 398, http://dx.
doi.org/10.1186/1471-2407-11-398.
[9] S. Huang, Y. Chen, W. Lee, I. Chang, Y. Chiu, Y. Chang, H. Tu, C. Yuh, I. Matsuura, L.
Shih, M. Lai, H.H. Wu, M. Chen, C. Yeh, Identiﬁcation of transforming hepatitis B
virus S gene nonsense mutations derived from freely replicative viruses in hepato-
cellular carcinoma, PLoS One (2014), http://dx.doi.org/10.1371/journal.pone.
0089753.
[10] S.A. Lee, K. Kim, H. Kim, B.J. Kim, Nucleotide change of codon 182 in the surface gene
of hepatitis B virus genotype C leading to truncated surface protein is associated
with progression of liver diseases, J. Hepatol. 56 (2012) 63–69.
[11] J. Skonier, M. Neubauer, L. Madisen, K. Bennett, G.D. Plowman, A.F. Purchio, cDNA
cloning and sequence analysis of beta ig-h3, a novel gene induced in a human ade-
nocarcinoma cell line after treatment with transforming growth factor-beta, DNA
Cell Biol. 11 (1992) 511–522.
[12] G.K. Klintworth, The molecular genetics of the corneal dystrophies— current status,
Front. Biosci. 1 (2003) 687–713.
[13] Y. Zhao, M. El-Cabry, T.K. Hei, Loss of Betaig-h3 protein is frequent in primary lung
carcinoma and related to tumorigenic phenotype in lung cancer cells, Mol. Carcinog.
45 (2006) 84–92.
[14] G. Calaf, C. Echiburu-Chau, Y.L. Zhao, T.K. Hei, BigH3 protein expression as a marker
for breast cancer, Int. J. Mol. Med. 21 (2008) 561–568.
[15] M.P. Ween, M.K. Oehler, C. Ricciardelli, Transforming growth factor-beta-induced
protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer,
Int. J. Cancer 13 (2012) 10461–10477.
[16] Y. Zhang, G.Wen, G. Shao, G.Wang, C. Lin, H. Fang, A.S. Balajee, G. Bhagat, T.K. Hei, Y.
Zhao, TGFBI deﬁciency predisposes mice to spontaneous tumor development, Can-
cer Res. 69 (2007) 37–44.
[17] B. Lin, A. Madan, J.G. Yoon, X. Fang, X. Yan, T.K. Kim, D. Hwang, L. Hood, G. Folz, Mas-
sively parallel signature sequencing and bioinformatics analysis identiﬁes upregula-
tion of TGFBI and SOX4 in human glioblastoma, PLoS One 5 (2010) e10210.
[18] C. Ma, Y. Rong, D.R. Radiloff, M.B. Datto, B. Centeno, S. Bao, A.W. Chen, F. Lin, S. Jiang,
T.J. Yeatman, X.F. Wang, Extracellular matrix protein betaig-h3/TGFBI promotesme-
tastasis of colon cancer by enhancing cell extravasation, Genes Dev. 22 (2008)
308–321.
[19] D.A. Zajchowski, M.F. Bartholdi, Y. Gong, L. Webster, H.L. Liu, A. Munishkin, C.
Beauheim, S. Harvey, S.P. Ethier, P.H. Johnson, Identiﬁcation of gene expressionproﬁles that predict the aggressive behavior of breast cancer cells, Cancer Res. 61
(2001) 5168–5178.
[20] I. Matsuura, C.Y. Lai, K.N. Chiang, Functional interaction between Smad3 and S100A4
(metastatin-1) for TGF-β-mediated cancer cell invasiveness, Biochem. J. 426 (2010)
327–335.
[21] S.S. Jiang,W.T. Fang, Y.H. Hou, S.F. Huang, B.L. Yen, J.L. Chang, S.M. Li, H.P. Liu, Y.L. Liu,
C.T. Huang, Y.W. Li, T.H. Jang, S.H. Chan, S.J. Yang, C.A. Hsiung, C.W. Wu, L.H. Wang,
Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation
of cell growth and tumorigenicity, Clin. Cancer Res. 16 (2010) 4363–4373.
[22] A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A.
Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, J.P. Mesirov, Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide expression
proﬁles, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15545–15550.
[23] S. Boyault, D.S. Rickman, A. de Reyniès, C. Balabaud, S. Rebouissou, E. Jeannot, A.
Hérault, J. Saric, J. Belghiti, D. Franco, P. Bioulac-Sage, P. Laurent-Puig, J. Zucman-
Rossi, Transcriptome classiﬁcation of HCC is related to gene alterations and to
new therapeutic targets, Hepatology 45 (2007) 42–52.
[24] G. Shao, J. Berenguer, A.C. Borczuk, C.A. Powell, T.K. Hei, Y. Zhao, Epigenetic inactiva-
tion of betaig-h3 gene in human cancer cells, Cancer Res. 66 (2006) 4566–4573.
[25] A.A. Ahmed, A.D. Mills, A.E. Ibrahim, J. Temple, C. Blenkiron, M. Vias, C.E. Massie, N.G.
Iyer, A.McGeoch, R. Crawford, B. Nicke, J. Downward, C. Swanton, S.D. Bell, H.M. Earl,
R.A. Laskey, C. Caldas, J.D. Brenton, The extracellular matrix protein TGFBI induces
microtubule stabilization and sensitizes ovarian cancers to paclitaxel, Cancer Cell
12 (2007) 514–527.
[26] J.N. Shah, G. Shao, T.K. Hei, Y. Zhao, Methylation screening of the TGFBI promoter in
human lung and prostate cancer by methylation-speciﬁc PCR, BMC Cancer 8 (2008)
284, http://dx.doi.org/10.1186/1471-2407-8-284.
[27] S. Kang, S.M. Dong, N.H. Park, Frequent promoter hypermethylation of TGFBI in ep-
ithelial ovarian cancer, Gynecol. Oncol. 118 (2010) 58–63.
[28] M. Suzuki, T. Yamada, F. Kihara-Negishi, T. Sakurai, E. Hara, D.G. Tenen, N. Hozumi, T.
Oikawa, Site speciﬁc DNA methylation by a complex of PU.1 and DNmt3a/b, Onco-
gene 25 (2006) 2477–2488.
[29] M. Tachibana, Y. Matsumura, M. Fukuda, H. Kimura, Y. Shinkai, G9a/GLP complexes
independentlymediate H3K9 and DNAmethylation to silence transcription, EMBO J.
27 (2008) 2681–2690.
[30] J.K. Jung, P. Arora, J.S. Pagano, K.L. Jang, Expression of DNAmethyltransferase 1 is ac-
tivated by hepatitis B virus X protein via a regulatory circuit involving the
p16INK4a–cyclin D1–CDK 4/6–pRb–E2F1 pathway, Cancer Res. 67 (2007)
5771–5778.
[31] Y.Z. Zhu, R. Zhu, L.G. Shi, Y. Mao, G.J. Zheng, Q. Chen, H.G. Zhu, Hepatitis B virus X
protein promotes hypermethylation of p16 (INK4A) promoter through upregula-
tion of DNA methyltransferases in hepatocarcinogenesis, Exp. Mol. Pathol. 89
(2010) 268–275.
[32] C. Gazin, N. Wajapeyee, S. Gobeil, C.M. Virbasius, M.R. Green, An elaborate pathway
required for Ras-mediated epigenetic silencing, Nature 449 (2007) 1073–1078.
[33] T.C. Wang, R.D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, E.V. Schmidt, Mammary hy-
perplasia and carcinoma in MMTV–cyclin D1 transgenic mice, Nature 369 (1994)
669–671.
[34] The American Joint Committee of Cancer, Cancer Staining Manual, sixth ed. Spring-
er, Heidelberg, 2002 (Part III, Liver).
